Trial
NCT04680637
Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Amgen
Collaborators
—
Condition
Active Systemic Lupus Erythematosus
Intervention
Efavaleukin Alfa
Why stopped
The trial was terminated prematurely as it met pre-defined criteria for futility at IA3.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-06-28